Mega Contracts Monitor ($100M+) — February 07, 2026

Three contracts worth $1.27B (30% of total) across DoT, HHS, GSA provide multi-decade revenue through 2041 in aviation IT and health R&D.

6 of 15 awards ($1.74B, 41%) to small, woman/minority-owned firms in IT, construction, remediation via set-asides/competitions.

5 GSA awards ($1.35B, 32%) in engineering, IT, construction signal preferred access for incumbents like HII, Brasfield & Gorrie.

Construction/remediation contracts ($892M) at ports, parks, CDC/NPS highlight $1T IIJA execution into 2029.

Long horizons (avg. 5+ years to 2041) with fixed-price/incentive terms expose to cost overruns in 9/15 contracts.

Subaward dependencies average 20% of obligation (e.g., $275M/439 in Kratos), risking delays in 10/15 contracts.

Zero/low initial outlays in new awards (e.g., HII $493M, Brasfield $263M) signal funding delays amid FY26 budget uncertainty.

Unexercised options average 20% uplift ($860M+ across portfolio) to base+options ceilings through 2030.

Health/defense R&D continuity ($1.1B via HHS/NASA/DoE) with extensions to 2029+ positions for follow-ons.

Small-cap capture of $1.74B offers undervalued entry amid federal set-aside tailwinds.

7 contracts ($1.9B) via GSA/DHS/VA for enterprise apps, LAN, support through 2029 signal multi-year incumbency.

Construction/environmental wins ($1.1B) at borders, parks, CDC, Moab underscore IIJA/IRA deployment.

$1B+ in HIV tests, NCI ops, CDC builds to 2027 provide predictable outlays (avg. 70% progressed).

{"entity"=>"Leidos Holdings", "reason"=>"1.27B awards = 30% volume, 20-yr ERAM tailwind to 2041", "trigger"=>"Q1 backlog >$35B or option exercises"}

{"entity"=>"Brasfield & Gorrie", "reason"=>"Two GSA builds ($383M) in ports/courts signal construction pipeline", "trigger"=>"Outlay ramp >50% in H1 2026"}

{"entity"=>"Small-disadvantaged firms (Synergy, North Wind)", "reason"=>"$435M wins validate 8(a)/HUBZone scale-up", "trigger"=>"Follow-on awards or M&A interest"}